Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIMJ8Z)

Drug Name

SKF 38393 Drug Info

Synonyms

SKF-38393; F-38393; 67287-49-4; F 38393; SKF38393; BRN 1543419; CHEMBL286080; 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-1-phenyl-1H-3-benzazepine-7,8-diol; 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; SKF-38,393; SK-38393; C16H17NO2; 5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 1-Phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Terminated	[1]

Cross-matching ID

PubChem CID: 1242
ChEBI ID: CHEBI:110200
CAS Number: CAS 67287-49-4
TTD Drug ID: DMIMJ8Z

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[6]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[7]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[8]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[9]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[10]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[11]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[12]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Catechol O-methyltransferase (COMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[3]
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[3]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[3]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[14]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[3]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[15]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catechol O-methyltransferase (COMT)	OTPWKTQG	COMT_HUMAN	Biotransformations	[3]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 935).
2	The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience. 1999;94(4):1063-70.
3	Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol. 2001 Feb;59(2):393-402. doi: 10.1124/mol.59.2.393.
4	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
7	Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
8	Clinical pipeline report, company report or official report of Lundbeck.
9	A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
10	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
11	trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
12	Clinical pipeline report, company report or official report of Lundbeck
13	Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
14	Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep. 2010 Aug;33(8):1027-35. doi: 10.1093/sleep/33.8.1027.
15	Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
16	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
17	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
18	Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord. 2001 Apr;7(2):93-96. doi: 10.1016/s1353-8020(00)00027-4.
19	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.